Cobert's Manual Of Drug Safety And Pharmacovigilance (Third Edition). William Gregory

Cobert's Manual Of Drug Safety And Pharmacovigilance (Third Edition) - William Gregory


Скачать книгу

      

       Published by

      World Scientific Publishing Co. Pte. Ltd.

      5 Toh Tuck Link, Singapore 596224

      USA office: 27 Warren Street, Suite 401-402, Hackensack, NJ 07601

      UK office: 57 Shelton Street, Covent Garden, London WC2H 9HE

       British Library Cataloguing-in-Publication Data

      A catalogue record for this book is available from the British Library.

       COBERT’S MANUAL OF DRUG SAFETY AND PHARMACOVIGILANCE 3rd Edition

      Copyright © 2019 by World Scientific Publishing Co. Pte. Ltd.

       All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the publisher.

      For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.

      ISBN 978-981-3278-84-4

      For any available supplementary material, please visit

       https://www.worldscientific.com/worldscibooks/10.1142/11228#t=suppl

      Typeset by Stallion Press

      Email: [email protected]

      Printed in Singapore

      Thank You

      Thanks to Chris Davis who saw enough merit in the first edition to publish a second edition and now a third edition. And thank you to Sandhya Devi MG and her team at World Publishing. Great to work with all of you!

      Thanks to our many colleagues in the drug safety world for their advice and clarification.

      Thank you to Dr. Lisa Beth Ferstenberg for her excellent chapter on vaccines and to Dr. Germano Ferreira for his review of the mathematics and epidemiology chapters.

      Barton Cobert: Thanks to Bill and Jean-Loup for taking much of the work and pressure off my shoulders!

      And again thanks to my loving and lovely wife Josiane for tolerating my hours in front of the computer.

      Jean-Loup Thomas: Thanks to all my colleagues and ex-colleagues who have been so professional and nice to work with.

      William Gregory: To Lauren and Carly for their incredible love, for giving me a sharper appreciation of lawyers and veterinarians, and for making my soul blossom every day. To my co-authors for being so smart and easy to work alongside, chapter by chapter.

      Contents

       Thank You

       Introductions

       Contributors

       Notice

       Chapter 1The Theory and Definitions of Drug Safety — Pharmacovigilance

       The Theory

       Adverse Event (AE) — ICH

       Adverse Event (AE) — EMA

       Adverse Event/Experience (AE) — FDA

       Adverse Reaction (AR)

       Serious Adverse Event and Serious Adverse Reaction (SAE/SAR)

       Non-serious Adverse Event and Non-serious Adverse Reaction (NSAE/NSAR)

       Suspected Adverse (Drug) Reaction (SAR/SADR) — FDA

       Serious, Unexpected, Suspected Adverse Reaction (SUSAR)

       Serious, Expected, Suspected Adverse Reaction

       Unexpected Adverse Event — FDA

       Unexpected Adverse Reaction — EMA

       Unlisted Adverse Reaction — EMA

       Expected (Listed versus Labeled)

       The Practice

       Chapter 2Clinical Trials, Clinical Research Organizations, Phases I–IV, and Investigator-Initiated Trials

       Introduction

       Phase I

       Phase II

       Phase III

       Phase IV

       Late Phase Studies

       Investigator-Initiated Research

       Other Study-Related Issues


Скачать книгу